Insider Trading April 16, 2026 08:52 PM

Director Michael Jaff Acquires $25,000 in HeartBeam Stock Tied to Public Offering

Jaff purchases 31,250 shares as HeartBeam completes $10 million offering led by ClearCardio and insiders

By Jordan Park BEAT
Director Michael Jaff Acquires $25,000 in HeartBeam Stock Tied to Public Offering
BEAT

Michael R. Jaff, a director of HeartBeam, reported buying 31,250 shares of the company's common stock on April 16, 2026, for $0.80 per share, totaling $25,000. The transaction was connected to HeartBeam's underwritten public offering of 12.5 million shares, which priced April 14 and closed April 16. HeartBeam also confirmed a $10 million sale of common stock and disclosed analyst coverage initiations from B. Riley and D. Boral Capital.

Key Points

  • Director Michael R. Jaff purchased 31,250 HeartBeam shares on April 16, 2026 at $0.80 per share, totaling $25,000.
  • HeartBeam closed a $10 million public offering of 12.5 million shares at $0.80 per share; Titan Partners acted as sole bookrunner and underwriters received a 30-day option for up to 1.875 million additional shares.
  • Analyst coverage was initiated by B. Riley (Buy, $4.00 target) and D. Boral Capital (Buy, $5.00 target); the offering included participation from ClearCardio, executives, and institutional investors - implications for healthcare, medical devices, and capital markets.

Director Michael R. Jaff disclosed an insider purchase of HeartBeam, Inc. (NASDAQ: BEAT) common stock on April 16, 2026. According to the filing, Jaff acquired 31,250 shares at $0.80 per share, representing a total outlay of $25,000. At the time of reporting the stock was trading at $0.81, close to its 52-week low of $0.54, after a year-to-date decline of 66%.

The purchase was executed in connection with HeartBeam's underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, served as the sole bookrunner for the deal, which was priced on April 14, 2026 and closed on April 16, 2026. The filing notes that the shares acquired by the reporting person are held indirectly through the entity Open Book Healthcare.

Separately, the company confirmed the closing of a $10 million public offering in which it sold 12.5 million shares at $0.80 per share. The offering list of participants included the company's first commercial customer, ClearCardio, as well as executive leadership and institutional investors. HeartBeam said the proceeds will be used to support the product rollout.

The company also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover any over-allotments. The disclosure indicated that the offering's completion was subject to customary closing conditions.

On the analyst front, B. Riley has initiated coverage of HeartBeam with a Buy rating and assigned a $4.00 price target, noting the company's FDA-cleared, cable-free ECG device. D. Boral Capital likewise began coverage with a Buy rating and a $5.00 price target. These coverage starts were highlighted alongside the financing activity in the company's disclosures.

InvestingPro analysis included with the filings states the stock appears undervalued at current levels, and notes that a Pro Research Report for HeartBeam is available on the platform. The filing and related disclosures provide a snapshot of insider activity, recent capital raising, and new analyst coverage, while also documenting the company's current trading range and the terms of the completed offering.


Contextual note: The details above are drawn from the company's insider filing and its offering disclosures. The statements regarding pricing, share counts, participants in the offering, and analyst initiations reflect the information presented in those documents.

Risks

  • The stock is trading near its 52-week low of $0.54 and has fallen 66% year-to-date, indicating continued market weakness for the shares - this impacts equity investors and market sentiment.
  • The offering's completion was subject to customary closing conditions, representing an execution risk related to the financing - relevant to the capital markets and corporate finance considerations.
  • Underwriters were granted a 30-day option to purchase up to 1,875,000 additional shares to cover over-allotments, which may affect outstanding share count depending on exercise - a factor for existing and prospective shareholders.

More from Insider Trading

Rakuten entities trim AST SpaceMobile stake in two-day $270 million sale Apr 16, 2026 Gloo Holdings CEO Makes Notable Insider Purchase Amid Mixed Financial Signals Apr 16, 2026 Gloo Holdings Director Patrick P. Gelsinger Acquires $264,634 of Class A Shares Apr 16, 2026 HeartBeam Director Richard Ferrari Purchases $50,000 of BEAT Stock Amid Recent Financing Apr 16, 2026 HeartBeam President Acquires $10,000 in Stock as Company Completes $10M Offering and Draws New Coverage Apr 16, 2026